Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2012

01-06-2012 | Research Articles

Biological markers of cisplatin resistance in advanced testicular germ cell tumours

Authors: Adelaida García-Velasco, Ignacio Durán, Elena García, Miquel Tarón, Claudio Ballestín, Daniel Castellanos, Hernán Cortés-Funés, Luis Paz-Ares

Published in: Clinical and Translational Oncology | Issue 6/2012

Login to get access
Metadata
Title
Biological markers of cisplatin resistance in advanced testicular germ cell tumours
Authors
Adelaida García-Velasco
Ignacio Durán
Elena García
Miquel Tarón
Claudio Ballestín
Daniel Castellanos
Hernán Cortés-Funés
Luis Paz-Ares
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Clinical and Translational Oncology / Issue 6/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0823-1

Other articles of this Issue 6/2012

Clinical and Translational Oncology 6/2012 Go to the issue

Research Articles

Expanding Sca-1+ mammary stem cell in the presence of oestrogen and growth hormone

Educational Series

Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles

Research Articles

Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC

Research Articles

Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience

Research Articles

Trends in prostate cancer survival in Spain: results from population-based cancer registries

Research Articles

Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits